BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 17078510)

  • 21. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
    Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
    Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances in veterinary vaccine adjuvants.
    Singh M; O'Hagan DT
    Int J Parasitol; 2003 May; 33(5-6):469-78. PubMed ID: 12782048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemical adjuvants for plasmid DNA vaccines.
    Greenland JR; Letvin NL
    Vaccine; 2007 May; 25(19):3731-41. PubMed ID: 17350735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel adjuvants and delivery systems for HIV vaccines.
    O'Hagan DT; Lavelle E
    AIDS; 2002; 16 Suppl 4():S115-24. PubMed ID: 12699008
    [No Abstract]   [Full Text] [Related]  

  • 25. The impact of new technologies on vaccines.
    Talwar GP; Diwan M; Razvi F; Malhotra R
    Natl Med J India; 1999; 12(6):274-80. PubMed ID: 10732430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contemporary approaches to designing and evaluating vaccines against Chlamydia.
    Igietseme JU; Eko FO; Black CM
    Expert Rev Vaccines; 2003 Feb; 2(1):129-46. PubMed ID: 12901604
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunity in response to particulate antigen-delivery systems.
    Storni T; Kündig TM; Senti G; Johansen P
    Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunomodulatory biomaterials.
    Mallapragada SK; Narasimhan B
    Int J Pharm; 2008 Dec; 364(2):265-71. PubMed ID: 18662761
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvants in perspective.
    Vogel FR
    Dev Biol Stand; 1998; 92():241-8. PubMed ID: 9554280
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heat shock proteins as vaccine adjuvants in infections and cancer.
    Segal BH; Wang XY; Dennis CG; Youn R; Repasky EA; Manjili MH; Subjeck JR
    Drug Discov Today; 2006 Jun; 11(11-12):534-40. PubMed ID: 16713905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines.
    Aucouturier J; Dupuis L; Deville S; Ascarateil S; Ganne V
    Expert Rev Vaccines; 2002 Jun; 1(1):111-8. PubMed ID: 12908518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An overview of adjuvant formulations and delivery systems.
    García A; De Sanctis JB
    APMIS; 2014 Apr; 122(4):257-67. PubMed ID: 23919674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanoparticles and microparticles as vaccine-delivery systems.
    Singh M; Chakrapani A; O'Hagan D
    Expert Rev Vaccines; 2007 Oct; 6(5):797-808. PubMed ID: 17931159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the innate immune response with improved vaccine adjuvants.
    Pashine A; Valiante NM; Ulmer JB
    Nat Med; 2005 Apr; 11(4 Suppl):S63-8. PubMed ID: 15812492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and evaluation of a DNA vaccine based on Helicobacter pylori urease B: failure to prevent experimental infection in the mouse model.
    Zavala-Spinetti L; Breslin MB; Correa H; Bégué RE
    Helicobacter; 2006 Dec; 11(6):517-22. PubMed ID: 17083372
    [TBL] [Abstract][Full Text] [Related]  

  • 37. European union regulatory developments for new vaccine adjuvants and delivery systems.
    Sesardic D; Dobbelaer R
    Vaccine; 2004 Jun; 22(19):2452-6. PubMed ID: 15193409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cationic liposomes as vaccine adjuvants.
    Christensen D; Korsholm KS; Andersen P; Agger EM
    Expert Rev Vaccines; 2011 Apr; 10(4):513-21. PubMed ID: 21506648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
    Cluff CW
    Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Innate immunity and new adjuvants.
    Mutwiri G; Gerdts V; Lopez M; Babiuk LA
    Rev Sci Tech; 2007 Apr; 26(1):147-56. PubMed ID: 17633299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.